18,000 Shares in Ocular Therapeutix, Inc. (OCUL) Purchased by State of Wisconsin Investment Board
State of Wisconsin Investment Board acquired a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 18,000 shares of the biopharmaceutical company’s stock, valued at approximately $167,000. State of Wisconsin Investment Board owned about 0.06% of Ocular Therapeutix as of its most recent SEC filing.
Several other large investors have also made changes to their positions in OCUL. American International Group Inc. grew its position in Ocular Therapeutix by 8.2% in the 1st quarter. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 844 shares during the last quarter. Highbridge Capital Management LLC bought a new position in shares of Ocular Therapeutix in the first quarter valued at approximately $107,000. Janney Montgomery Scott LLC bought a new position in shares of Ocular Therapeutix in the first quarter valued at approximately $110,000. Rhumbline Advisers boosted its holdings in shares of Ocular Therapeutix by 22.1% in the second quarter. Rhumbline Advisers now owns 27,386 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 4,958 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Ocular Therapeutix by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $284,000 after acquiring an additional 401 shares in the last quarter. 53.42% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on OCUL shares. ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th. Morgan Stanley downgraded shares of Ocular Therapeutix from an “overweight” rating to an “equal weight” rating and set a $16.00 price target for the company. in a research report on Friday, June 23rd. Zacks Investment Research downgraded shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Cantor Fitzgerald set a $35.00 price target on shares of Ocular Therapeutix and gave the company a “buy” rating in a research report on Monday, July 10th. Finally, BTIG Research reiterated a “neutral” rating on shares of Ocular Therapeutix in a research report on Monday, July 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $22.14.
Ocular Therapeutix, Inc. (NASDAQ OCUL) opened at 6.49 on Friday. Ocular Therapeutix, Inc. has a 12-month low of $4.82 and a 12-month high of $11.91. The stock’s 50 day moving average is $6.09 and its 200-day moving average is $8.35. The company’s market capitalization is $188.57 million.
Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.05). Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.51 million. During the same quarter last year, the company posted ($0.46) earnings per share. The company’s revenue was up .0% on a year-over-year basis. On average, equities analysts predict that Ocular Therapeutix, Inc. will post ($2.25) earnings per share for the current fiscal year.
Ocular Therapeutix Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Receive News & Stock Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related stocks with our FREE daily email newsletter.